No takes yet. Share an insight, caveat, or question.
Phase II trial showed Ribociclib plus Letrozole improved progression-free survival in women with recurrent LGSOC, suggesting a new therapeutic option.
Slomovitz et al. (2025) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: